Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors
- PMID: 31820981
- DOI: 10.1021/acs.jmedchem.9b01180
Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors
Abstract
KRASG12C has emerged as a promising target in the treatment of solid tumors. Covalent inhibitors targeting the mutant cysteine-12 residue have been shown to disrupt signaling by this long-"undruggable" target; however clinically viable inhibitors have yet to be identified. Here, we report efforts to exploit a cryptic pocket (H95/Y96/Q99) we identified in KRASG12C to identify inhibitors suitable for clinical development. Structure-based design efforts leading to the identification of a novel quinazolinone scaffold are described, along with optimization efforts that overcame a configurational stability issue arising from restricted rotation about an axially chiral biaryl bond. Biopharmaceutical optimization of the resulting leads culminated in the identification of AMG 510, a highly potent, selective, and well-tolerated KRASG12C inhibitor currently in phase I clinical trials (NCT03600883).
Similar articles
-
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.Nature. 2019 Nov;575(7781):217-223. doi: 10.1038/s41586-019-1694-1. Epub 2019 Oct 30. Nature. 2019. PMID: 31666701 Clinical Trial.
-
Beyond KRAS(G12C): Biochemical and Computational Characterization of Sotorasib and Adagrasib Binding Specificity and the Critical Role of H95 and Y96.ACS Chem Biol. 2024 Oct 18;19(10):2152-2164. doi: 10.1021/acschembio.4c00315. Epub 2024 Sep 16. ACS Chem Biol. 2024. PMID: 39283696
-
Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation.Cancer Discov. 2021 Aug;11(8):1913-1922. doi: 10.1158/2159-8290.CD-21-0365. Epub 2021 Apr 6. Cancer Discov. 2021. PMID: 33824136 Free PMC article.
-
Targeting mutant KRAS.Curr Opin Chem Biol. 2021 Jun;62:101-108. doi: 10.1016/j.cbpa.2021.02.010. Epub 2021 Apr 7. Curr Opin Chem Biol. 2021. PMID: 33838397 Review.
-
Inhibition of RAS: proven and potential vulnerabilities.Biochem Soc Trans. 2020 Oct 30;48(5):1831-1841. doi: 10.1042/BST20190023. Biochem Soc Trans. 2020. PMID: 32869838 Free PMC article. Review.
Cited by
-
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.J Hematol Oncol. 2022 Oct 8;15(1):143. doi: 10.1186/s13045-022-01362-9. J Hematol Oncol. 2022. PMID: 36209184 Free PMC article. Review.
-
Implementation of an AI-assisted fragment-generator in an open-source platform.RSC Med Chem. 2022 Aug 15;13(10):1205-1211. doi: 10.1039/d2md00152g. eCollection 2022 Oct 19. RSC Med Chem. 2022. PMID: 36320432 Free PMC article.
-
Genomic Alterations of NTRK, POLE, ERBB2, and Microsatellite Instability Status in Chinese Patients with Colorectal Cancer.Oncologist. 2020 Nov;25(11):e1671-e1680. doi: 10.1634/theoncologist.2020-0356. Epub 2020 Aug 10. Oncologist. 2020. PMID: 32627883 Free PMC article.
-
Structure-Based Design and Evaluation of Reversible KRAS G13D Inhibitors.ACS Med Chem Lett. 2023 Dec 6;15(1):21-28. doi: 10.1021/acsmedchemlett.3c00478. eCollection 2024 Jan 11. ACS Med Chem Lett. 2023. PMID: 38229748 Free PMC article.
-
An overview of recent advancements in small molecules suppression of oncogenic signaling of K-RAS: an updated review.Mol Divers. 2024 Dec;28(6):4581-4608. doi: 10.1007/s11030-023-10777-6. Epub 2024 Jan 30. Mol Divers. 2024. PMID: 38289431 Review.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Molecular Biology Databases
Miscellaneous